Soligenix announces accelerated publication demonstrating efficacy and broad neutralizing activity of its covid-19 vaccine in non-human primates

Princeton, n.j., sept. 28, 2021 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of pre-clinical immunogenicity studies for civax™ (heat stable covid-19 vaccine program) demonstrating durable broad-spectrum neutralizing antibody responses, including against the beta, gamma and delta variants of concern.
SNGX Ratings Summary
SNGX Quant Ranking